 Rilpivirine was approved by the FDA for HIV therapy in May 2011 under the brand name Edurant.Edurant is approved for treatment-naive patients with a viral load of 100,000 copies/mL or less at therapy initiation.Its recommended dosage is 25 mg orally once daily with a meal, in combination with other antiretrovirals.